lung cancer Archives

Novel lung cancer biomarker

Jan. 9, 2023—Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.

Lovly receives Asclepios Award from GO2 for Lung Cancer

Dec. 8, 2022—Vanderbilt's Christine Lovly, MD, PhD, has received the 2022 Asclepios Award, which recognizes lung cancer research pioneers.

Event set to make lung cancer screening more accessible

Oct. 20, 2022—Vanderbilt University Medical Center is making the lung cancer screening more convenient with weekend appointments from 8 a.m. to noon on Saturday, Nov. 12, at Vanderbilt Health One Hundred Oaks

Policy, resources crucial for lung cancer screening: study

Sep. 29, 2022—Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened.

Members of the newly named MASLAB gathered for a portrait on the Medical Center Plaza. The early lung cancer detection research initiative was named in honor of the late Pierre Massion, MD.

Lung cancer detection program lands grant renewal

Sep. 15, 2022—The National Cancer Institute has renewed funding for the Early Detection Research Network Lung Cancer Clinical Validation Center at Vanderbilt- Ingram Cancer Center.

Targeted cancer drug during pregnancy

Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.

H. pylori and lung cancer

Aug. 1, 2022—Specific biomarkers for H. pylori — a bacterium that infects the stomach — were associated with increased risk of lung cancer, Vanderbilt researchers have discovered.

Study reveals need for matching targeted therapies with EGFR subtypes

Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

Shown at Monday’s VICC Annual Scientific Retreat are (front row, from left) Timothy Blackwell, MD, Fabien Maldonado, MD, Denise Aberle, MD, Melinda Aldrich, PhD, MPH, Kim Sandler, MD, (back row, from left) Eric Grogan, MD, MPH, Sudhir Srivastava, PhD, MPH, M. Patricia Rivera, MD, Julien Sage, PhD, David Carbone, MD, PhD, and Scott Hiebert, PhD.

VICC Scientific Retreat focuses on lung cancer

May. 5, 2022—by Tom Wilemon Speakers at the Vanderbilt-Ingram Cancer Center (VICC) 23rd Annual Scientific Retreat celebrated “Advances in Lung Cancer Research” but noted that too many people with the disease are not benefiting from those achievements. “Lung cancer is our leading cause of cancer mortality. Twenty-nine percent of our total cancers are lung cancer. That’s the...

Molecular testing across tumor types

Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

AI used to identify patients at risk for lung cancer

Dec. 16, 2021— by Matt Batcheldor The Vanderbilt Lung Institute is the first location in Tennessee to debut Optellum Virtual Lung Nodule Clinic comprehensive management software that, using artificial intelligence, can identify and track patients at risk for lung cancer — even if they have never been in for a cancer screening. That’s because the Optellum software...

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

Sep. 23, 2021— by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...